Naltrexone Medically Assisted Therapy
Clarity Intensive Outpatient Opiate Treatment (IOOT™) uses a revolutionary process to get – and keep – users clean. Naltrexone, a drug that blocks the effects of opiates, aids in cessation of cravings and withdrawal. Unlike traditional detox programs, Clarity does not trade one opiate for another.
Naltrexone is known as an opioid receptor antagonist. That means it literally blocks parts of the brain – receptors – that crave opiates and get high from them. It’s been credited with significantly speeding not only the rate of recovery but its success.
Naltrexone is used in four forms for the IOOT™ treatment. Delivery forms to maximize compliance and the rapid saturation include IV, biodegradable implant, oral, and IM injection. Monthly support can be done by simple painless injection (IM) received at the treatment center or a selected medical professional local to you. Traditional detox programs often use Suboxone or Methadone, both actuality opiates, to gradually wean patients off opioids. Opiate substitutes are taken daily, are not always readily available and require great discipline among patients.
Unlike Suboxone or Methadone, Naltrexone has no potential for abuse because it is not an opiate.
Once used solely for treating alcohol dependence, Naltrexone was approved in 2010 by the Food and Drug Administration for the treatment of opioid dependence. The Department of Health and Human Services now recommends medication-assisted treatment with counseling – like Clarity’s patented process – as a best choice for opioid addiction. “If you are addicted, medication allows you to regain a normal state of mind, free of drug-induced highs and lows. It frees you from thinking all the time about the drug. It can reduce problems of withdrawal and craving.”
A 2011 study among 250 patients in Russia found that 90 percent of patients stayed off opioids. A study presented to the American Psychiatric Association found that those treated with Naltrexone have significantly lower rates of relapse, prompting the FDA’s director of drug evaluation and research, Dr. Janet Woodcock, to conclude that it is a “significant advancement in addiction treatment.”
The U.S. Substance Abuse and Mental Health Services Administration puts it simply: “Naltrexone blocks opioids from acting on the brain, so it takes away the reward of getting high on the problem drug.”
Visit The Substance Abuse and Mental Health Services Administration website at samhsa.gov.